Literature DB >> 8546525

Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis?

H R Barthel1, G R Burmester.   

Abstract

The complexity of RA challenges our search for a better understanding of the interconnected networks. Early treatment will certainly avoid some of the problems presented by the complexity of the disease, and combined treatments seem advantageous for advanced disease. The complexity of overt RA will probably not allow a single agent to exert superior efficacy. Unless a treatable infectious cause is identified, a magic bullet, though theoretically possible, might not exist in reality, in particular if the disease is advanced.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8546525      PMCID: PMC1010057          DOI: 10.1136/ard.54.12.948

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis.

Authors:  G S Firestein; J M Alvaro-Gracia; R Maki; J M Alvaro-Garcia
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

2.  Prolonged remission of severe refractory rheumatoid arthritis following allogeneic bone marrow transplantation for drug-induced aplastic anaemia.

Authors:  P Jacobs; M D Vincent; R W Martell
Journal:  Bone Marrow Transplant       Date:  1986-12       Impact factor: 5.483

Review 3.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

Authors:  P K Gregersen; J Silver; R J Winchester
Journal:  Arthritis Rheum       Date:  1987-11

4.  Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma.

Authors:  E M Lemmel; D Brackertz; M Franke; W Gaus; P W Hartl; K Machalke; H Mielke; H J Obert; H H Peter; J Sieper
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

5.  Increased frequency of V beta 17-positive T cells in patients with rheumatoid arthritis.

Authors:  G Zagon; J R Tumang; Y Li; S M Friedman; M K Crow
Journal:  Arthritis Rheum       Date:  1994-10

6.  Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis.

Authors:  G W Cannon; S H Pincus; R D Emkey; A Denes; S A Cohen; F Wolfe; P A Saway; A M Jaffer; A L Weaver; L Cogen
Journal:  Arthritis Rheum       Date:  1989-08

7.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; J R Kalden; C Antoni; J S Smolen; B Leeb; F C Breedveld; J D Macfarlane; H Bijl
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

Review 8.  New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm.

Authors:  L W Moreland; L W Heck; W Sullivan; P W Pratt; W J Koopman
Journal:  Am J Med Sci       Date:  1993-01       Impact factor: 2.378

9.  Effects of oral administration of type II collagen on rheumatoid arthritis.

Authors:  D E Trentham; R A Dynesius-Trentham; E J Orav; D Combitchi; C Lorenzo; K L Sewell; D A Hafler; H L Weiner
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

10.  A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis.

Authors:  P A van der Lubbe; B A Dijkmans; H M Markusse; U Nässander; F C Breedveld
Journal:  Arthritis Rheum       Date:  1995-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.